17 results
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:17pm
in which we operate to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:11pm
incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential
8-K
EX-10.1
bh4of7k
16 May 23
Entry into a Material Definitive Agreement
8:30am
424B5
rzla3 ouqia
8 May 23
Prospectus supplement for primary offering
5:19pm
424B5
qzsildl 58l6
8 May 23
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.1
idw6n
21 Dec 22
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
8:37am
424B5
dive55 sui9r2mvb3
9 Nov 22
Prospectus supplement for primary offering
4:29pm
10-Q
1mjhdo02ai5ui37y8qjp
8 Nov 22
Quarterly report
4:09pm
424B5
r8z kbofskf
21 Oct 22
Prospectus supplement for primary offering
4:16pm
8-K
EX-99.1
mxk74wuss5u8xr4gqbn
19 Oct 22
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
6:26am
424B5
ph6m0 52sg83m58ixw8
13 Oct 22
Prospectus supplement for primary offering
4:56pm
- Prev
- 1
- Next